Year Founded
2015
Ownership
Private
Employees
~100
Stage
Phase 2
Modalities
Cytokine therapyProtein therapeuticsNatural killer cell therapy (NK cell therapy)

Dragonfly Therapeutics General Information

Multiple programs in clinical development including DF1001 (HER2 TriNKET) in Phase 2, DF9001 (EGFR TriNKET) in Phase 1, and DF6215 (IL-2 cytokine) in Phase 1/1b. Showed encouraging Phase 1 results with DF1001.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

DF1001
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Dragonfly Therapeutics's pipeline data

Book a demo

Key Partnerships

AbbVie, Bristol Myers Squibb, Gilead, Merck

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Dragonfly Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Dragonfly Therapeutics's complete valuation and funding history, request access »